July 3rd 2025
Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved patient outcomes across diverse populations.
ICI Treatment Necessitates Close Monitoring of Potential Myasthenia Gravis